# Alnylam Pharmaceuticals, Inc. (ALNY) stock news and updates

As of November 19, 2026. Source: https://www.clearthesis.ai/updates/ALNY

## Our view on the Alnylam Pharmaceuticals, Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/ALNY

## Latest updates on Alnylam Pharmaceuticals, Inc.

### FDA approves seventh drug from Alnylam's platform

*November 19, 2026 · product · significance: notable · signal: positive*

The U.S. Food and Drug Administration approved Livsayis, a treatment for generalized myasthenia gravis, a chronic condition that causes muscle weakness and fatigue. While the drug was developed and will be sold by Regeneron, it was originally discovered using Alnylam's RNA interference technology, which works by silencing the specific genes that cause disease. This is the seventh drug from Alnylam's platform to be approved in less than nine years. For a long-term owner, this is a clear sign that the company's core technology is reliable and repeatable. While Alnylam won't keep all the profits from this specific drug, the approval validates its ability to discover successful treatments that other major drugmakers are willing to bet on.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261119295782/en/Alnylam-Collaborator-Regeneron-Secures-FDA-Approval-of-Livsayis%E2%84%A2-cemdisiran-the-Seventh-FDA-Approved-Therapeutic-from-Alnylams-RNAi-Platform-in-Less-Than-Nine-Years/)

### Early trial shows liver disease drug rapidly clears liver fat

*November 11, 2026 · news · significance: notable · signal: positive*

Alnylam and its partner Regeneron shared early results for a new treatment targeting MASLD, a common condition where fat builds up in the liver and causes damage. In the first study on humans, a single injection quickly returned liver fat to normal levels and improved markers of liver health. This is a positive step for Alnylam because it shows their gene-silencing technology works for this specific liver target. While this is only an early trial, the ability to normalize fat levels with one dose suggests the drug could eventually compete in a large and growing market for metabolic liver diseases.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261110694883/en/Alnylam-Collaborator-Regeneron-Advances-CIDEBsiRNA-with-Promising-First-in-Human-Results-in-Patients-with-MASLD/)

### Five-year data shows heart drug Amvuttra has lasting benefits

*November 10, 2026 · news · significance: notable · signal: positive*

Alnylam shared new data from a long-term study of Amvuttra, its treatment for a specific type of heart disease caused by protein buildup. The results show that the drug continues to work well for patients five years after they started treatment, helping to keep them out of the hospital and reducing the risk of death. This is important because Amvuttra is the company's biggest source of growth. Proving that the drug is safe and effective over many years helps cement its place as a standard treatment for this condition. For a long-term owner, this adds confidence that the drug's sales can remain steady as more patients stay on the therapy for longer periods.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261109441010/en/Alnylam-Announces-Five-Year-HELIOS-B-Data-Demonstrating-Sustained-Benefit-of-AMVUTTRA%C2%AE-vutrisiran-in-ATTR-CM/)

### Alnylam plans to buy back $1 billion of its own stock

*November 5, 2026 · filing · significance: notable · signal: positive*

Alnylam's board authorized a plan to buy back up to $1 billion of its own shares, with about $500 million expected to be completed by the end of 2026. A buyback is when a company uses its cash to buy its own stock from the market, which reduces the total number of shares and makes each remaining share own a larger piece of the business. Separately, the company announced that Tolga Tanguler, the Chief Commercialization Officer, will leave his role in December 2026. While leadership changes can sometimes be unsettling, this appears to be an orderly transition as the company moves into a new phase of growth. The buyback is a strong signal that management believes the stock is undervalued after its recent drop.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000080/0001178670-26-000080-index.htm)

### Alnylam to share long-term heart drug data at upcoming conferences

*November 5, 2026 · news · significance: minor · signal: neutral*

Alnylam will present new five-year clinical data for Amvuttra, its treatment for a specific type of heart disease, at the American Heart Association meeting starting November 6. These presentations are routine for biotech companies, but they provide the medical community with evidence of how well a drug works over several years. For long-term owners, this data helps confirm whether the drug can maintain its lead in a competitive market.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261103351345/en/Alnylam-to-Present-Five-Year-HELIOS-B-Data-and-Expanding-Evidence-on-the-Benefits-of-RNAi-Powered-TTR-Silencing-with-AMVUTTRA%C2%AE-vutrisiran-at-AHA-and-ISA-2026/)

## Alnylam Pharmaceuticals, Inc. earnings

In Q3 2026, reported on October 29, 2026, Alnylam Pharmaceuticals, Inc. posted earnings of $16.26 per share against $1.66 expected, and revenue of $1.5 billion against $1.4 billion expected.

The next earnings report is expected on February 11, 2027. Analysts expect $1.72 per share. Revenue is expected around $1.5 billion.

What to watch: Whether operating margin stays on its path toward 25 percent, which would prove the company can finally turn its fast-growing sales into steady profit.

## Recent analyst activity on ALNY

- November 18, 2026: J.P. Morgan Set target. Price target: $254.00.
- November 2, 2026: Barclays Kept rating at Overweight.
- November 2, 2026: Canaccord Genuity Kept rating at Buy.
- November 2, 2026: Truist Securities Downgraded to Hold.
- October 30, 2026: TD Cowen Kept rating at Buy.
- October 30, 2026: Goldman Sachs Kept rating at Buy.

## What's ahead for Alnylam Pharmaceuticals, Inc.

- February 11, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/ALNY
